摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

phenyl 2-azido-2-deoxy-1-thio-D-glucopyranoside | 202462-37-1

中文名称
——
中文别名
——
英文名称
phenyl 2-azido-2-deoxy-1-thio-D-glucopyranoside
英文别名
Amberlite;phenyl-2-azido-2-deoxy-1-thio-D-glucopyranose;phenyl 2-deoxy-2-azidothio-D-glucopyranoside;phenyl 2-azido-2-deoxy-1-thio-α/β-D-glucopyranoside;(2R,3S,4R,5R)-5-azido-2-(hydroxymethyl)-6-phenylsulfanyloxane-3,4-diol
phenyl 2-azido-2-deoxy-1-thio-D-glucopyranoside化学式
CAS
202462-37-1
化学式
C12H15N3O4S
mdl
——
分子量
297.335
InChiKey
VDPWHERVMHFLNT-PRFVCTMUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    110
  • 氢给体数:
    3
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3

反应信息

点击查看最新优质反应信息

文献信息

  • Scalable Synthesis of Anomerically Pure Orthogonal-Protected GlcN<sub>3</sub> and GalN<sub>3</sub> from <scp>d</scp>-Glucosamine
    作者:Emil Glibstrup、Christian Marcus Pedersen
    DOI:10.1021/acs.orglett.6b02241
    日期:2016.9.2
    An improved and scalable synthesis of orthogonally protected d-glucosamine and d-galactosamine building blocks from inexpensive d-glucosamine has been developed. The key reaction is an inversion/migration step providing access to a fully orthogonal protecting group pattern, which is required for microbial oligosaccharide synthesis. The method can be carried out on a multigram scale as several of the
    已经开发了由廉价的d-葡糖胺合成的正交保护的d-葡糖胺和d-半乳糖胺结构单元的改进的和可扩展的合成。关键反应是转化/迁移步骤,该步骤可提供微生物寡糖合成所需的完全正交的保护基团模式。该方法可以在数克范围内进行,因为可以通过结晶纯化一些反应以得到端基纯的产物。
  • Improvement of the stereoselectivity of the glycosylation reaction with 2-azido-2-deoxy-1-thioglucoside donors
    作者:E.C. Lourenço、M.R. Ventura
    DOI:10.1016/j.carres.2016.03.021
    日期:2016.5
    2-Azido-2-deoxy-1-thioglucoside donors with an electron withdrawing group at position 6 were employed to study the stereoselectivity of the glycosylation reaction with several acceptors, ranging from unhindered small primary alcohols to other sugars and steroids, using NIS/TfOH as promoter. p-Tolyl 2-azido-3,4-di-O-benzyl-6-O-chloroacetyl-2-deoxy-1-thio-α/β-D-glucopyranoside afforded the higher α-selectivity
    使用NIS / TfOH,使用在6位具有吸电子基团的2-叠氮基2--1-葡萄糖苷供体来研究糖基化反应与多个受体的立体选择性,这些受体的范围从无阻碍的小型伯醇到其他糖和类固醇作为发起人。对甲苯基2-叠氮基-3,4-二-O-苄基-6-O-乙酰基-2--1-代-α/β-D-吡喃葡萄糖苷具有较高的α-选择性,表明电子更强在O-6处提取影响了对1,2-顺式葡糖苷的异头异构体选择性。端基异构体的立体选择性高度依赖于受体。
  • [EN] A METHOD FOR OBTAINING CRYSTALLINE LACTO-N-TETRAOSE AND LACTO-N-NEOTETRAOSE PRECURSORS AND MIXTURES THEREOF<br/>[FR] PROCÉDÉ POUR OBTENIR DES PRÉCURSEURS DE LACTO-N-TÉTRAOSE ET DE LACTO-N-NEOTÉTRAOSE CRISTALLIN ET DES MÉLANGES DE CEUX-CI
    申请人:GLYCOM AS
    公开号:WO2013091660A1
    公开(公告)日:2013-06-27
    A mixture of, preferably a mixture consisting essentially of, an lacto-N-tetraose (LNT) precursor (1) and an lacto-N-neotetraose (LNnT) precursor (2), (formula 1, 2), where R is a group removable by hydrogenolysis and R3 is either a group removable by hydrogenolysis or H, a method of crystallizing 1 and/or 2 from said mixture, and the use of said mixture for making a mixture consisting essentially of LNnT and LNT for use as a pharmaceutically or nutritionally active ingredient. The precursors can be made by reacting an acceptor of formula 5, (formula 5), wherein R is a group removable by hydrogenolysis, R1 is acyl, Ri is acyl or H, R3 is selected from a group removable by hydrogenolysis, acyl, silyl and an acetal type group and Y is selected from alkanoylamido, haloalkanoylamido, -NAc2, benzamido, alkoxycarbonylamino, haloalkoxycarbonylamino, benzyloxycarbonylamino, azido, phthalimido, tetrachlorophthalimido, 2,3- diphenylmaleimido and 2,3-dimethylmaleimido, with a donor of formula 6, (formula 6), wherein R4 is acyl and Xi is selected from halogen, -OC(=NH)CCl3, -OAc, -OBz or -SR5, wherein R5 is selected from alkyl, substituted phenyl and unsubstituted phenyl, followed by one or more deprotection steps.
    一种混合物,优选基本上由乳糖-N-四糖(LNT)前体(1)和乳糖-N-新四糖(LNNT)前体(2)(式1,2)组成,其中R是通过解可移除的基团,R3是可通过解移除的基团或H,从该混合物中结晶1和/或2的方法,以及该混合物用于制备基本上由LNNT和LNT组成的混合物,作为药用或营养活性成分的用途。这些前体可以通过反应一个受体式5(式5),其中R是通过解可移除的基团,R1是酰基,Ri是酰基或H,R3是从可通过解移除的基团、酰基、基和缩醛型基团中选择的,Y是从烷酰胺基、卤代烷酰胺基、-NAc2、酰胺基、烷羰基基、卤代烷羰基基、苄羰基基、叠氮基、邻二甲酰亚胺基、四二甲酰亚胺基、2,3-二基马来酰亚胺基和2,3-二甲基马来酰亚胺基中选择的,与一个供体式6(式6)反应,其中R4是酰基,Xi是从卤素、-OC(=NH)CCl3、-OAc、-OBz或-SR5中选择的,其中R5是从烷基、取代的基和未取代的基中选择的,随后进行一个或多个保护步骤来制备。
  • [EN] DI- AND TRI-CATIONIC GLYCOSYLATED ANTITUMOR ETHER LIPIDS, L-GUCOSYLATED GAELS AND RHAMNOSE-LINKED GAELS AS CYTOTOXIC AGENTS AGAINST EPITHELIAL CANCER CELLS AND CANCER STEM CELLS<br/>[FR] ETHERS LIPIDIQUES ANTITUMORAUX GLYCOSYLÉS DI- ET TRICATIONIQUES, GAEL L-GLYCOSYLÉS ET GAEL LIÉS À DU RHAMNOSE UTILISABLES EN TANT QU'AGENTS CYTOTOXIQUES DIRIGÉS CONTRE DES CELLULES ÉPITHÉLIALES CANCÉREUSES ET DES CELLULES SOUCHES CANCÉREUSES
    申请人:UNIV MANITOBA
    公开号:WO2015179983A1
    公开(公告)日:2015-12-03
    Glycosylated Antitumor Ether Lipids (GAELs) kill cancer cells by a nonapoptotic pathway which is an attractive strategy to avoid resistance. To further optimize the antitumor effect, we prepared various analogs of di-, and tri-cationic GAEL analogs differing in the nature of the sugar (D-giucose or L-glucose), the anomeric linkage as well as position of the glycerolipid moiety. The di- and tri-cationic GAELs were synthesized and their in vitro anticancer properties were evaluated against drug resistant and aggressively growing cancer cell lines derived from human breast, prostate, pancreatic and ovarian cancers. The most potent dicationic GAEL analogs were also studied against cancer stem cells obtained from breast BT 474, prostate DU145 and ovarian A2780cp cell lines. Our results indicate that the number of positive charges, the position of the amino substituents and the nature of the sugar have significant effects on the anticancer activities of these compounds. The most active analog kill 50% of the cells at concentration range of 0.5-5μΜ and 90% of the cells at the concentration of 1-10μΜ depending on type of cancer cells.
    糖基化抗肿瘤醚脂质(GAELs)通过一种非凋亡途径杀灭癌细胞,这是一种吸引人的策略,可以避免抗药性。为了进一步优化抗肿瘤效果,我们制备了不同的双-和三-阳离子GAEL类似物,其糖的性质(D-葡萄糖或L-葡萄糖)、缩醛键以及甘油脂类团的位置不同。合成了双-和三-阳离子GAEL类似物,并评估了它们对人类乳腺、前列腺、胰腺和卵巢癌衍生的耐药和快速生长的癌细胞系的体外抗癌性能。最有效的双阳离子GAEL类似物也针对从乳腺BT 474、前列腺DU145和卵巢A2780cp细胞系中获得的癌干细胞进行了研究。我们的结果表明,阳离子数量、基取代物的位置和糖的性质对这些化合物的抗癌活性有显著影响。最活跃的类似物在浓度范围为0.5-5μΜ时杀死50%的细胞,在浓度为1-10μΜ时杀死90%的细胞,具体取决于癌细胞类型。
  • Design, synthesis and evaluation of cytotoxic properties of bisamino glucosylated antitumor ether lipids against cancer cells and cancer stem cells
    作者:Makanjuola Ogunsina、Pranati Samadder、Temilolu Idowu、Gilbert Arthur、Frank Schweizer
    DOI:10.1039/c6md00328a
    日期:——
    diamino-D-gluco-based GAELs and their analogs, and screened them against a panel of human epithelial cancer cell lines and cancer stem cells. Most of the new GAEL analogs are more potent than chlorambucil, cisplatin and salinomycin. The most potent bisamine-based GAEL analogs 1, 2, 4 and 8 showed 2- to 3-fold enhanced cytotoxicity against various cancer cell lines when compared to β-GLN, indicating that the addition
    糖基化抗肿瘤醚脂质(GAEL)是一类通过非凋亡途径杀死癌细胞的两亲性抗肿瘤药。以前的研究已经表明,2-基-2-d -葡萄糖基础的盖尔如α-GLN和β-GLN显示出大大改善的抗上皮癌细胞的抗肿瘤活性和干细胞。为了进一步优化生物活性,我们制备了一系列二基的d -葡糖基础的盖尔和它们的类似物,并筛选它们免受人类上皮癌细胞系和癌症干细胞的一个面板。大多数新的GAEL类似物比苯丁酸氮芥顺铂沙利霉素更有效。最有效的基于双胺的GAEL类似物1,与β-GLN相比,图2,图4和图8显示出对各种癌细胞系的细胞毒性提高了2-3倍,这表明添加第二个基基团增强了细胞毒性作用。活性最高的GAEL 1和4对分离自乳腺癌(BT-474)和前列腺(DU-145)细胞系的癌症干细胞的影响表明,两种GAEL抑制肿瘤球的形成并导致> 95%的损失5μM时癌症干细胞的活力 GAEL 1对BT-474癌症干细胞的活性优于沙利霉素
查看更多